CELL THERAPEUTICS
Cell Therapeutics, Inc. Completes Registered Direct Offering
Cell Therapeutics, Inc. Completes Registered Direct Offering
SEATTLE, December 22/PRNewswire/ --
Cell Therapeutics, Inc. (Nasdaq: CTIC; Nuovo Mercato) today
announced that it has completed the previously announced sale of
approximately 2,586,000 shares of its common stock to several
institutional investors at a negotiated price per share of US$7.10.
About Cell Therapeutics, Inc.
Headquartered in Seattle, CTI is a biopharmaceutical company
committed to developing an integrated portfolio of oncology products
aimed at making cancer more treatable. For additional information,
please visit www.cticseattle.com.
Web site: http://www.cticseattle.com
Source: Cell Therapeutics, Inc.
investors, Leah Grant of Cell Therapeutics, Inc., +1-206-282-7100, or
fax, +1-206-272-4434, or invest@ctiseattle.com, or
www.cticseattle.com/investors.htm; or Cesare Parachini of Cell
Therapeutics, Inc. (Europe), 39 026 103 5807, or fax,
+39-026-103-5601, or cesare.parachini@ctimilano.com
22 dec 04 13:23